Karvea

Irbesartan, the active ingredient in Karvea, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is employed to lower blood pressure and to protect the kidneys in patients with diabetes, as well as to support heart failure management in adult patients.

GNH USA supplies Karvea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Karvea acts on the renin‑angiotensin‑aldosterone system to control blood pressure and related organ damage.

Hypertension: lowers systolic and diastolic pressure, reducing cardiovascular risk. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. Heart failure: improves symptoms and reduces hospitalisation by decreasing afterload.

Karvea may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Upper respiratory tract infection - Mild gastrointestinal discomfort - Elevated blood potassium levels

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Acute kidney injury or worsening renal function - Severe hyperkalemia - Symptomatic hypotension - Hepatic injury or abnormal liver enzymes

Before initiating Karvea, clinicians should assess several safety parameters.

Renal function: monitor serum creatinine and eGFR at baseline and periodically. Electrolytes: check potassium levels before and during therapy. Pregnancy: avoid use because fetal toxicity has been reported. Concomitant drugs: review potassium‑sparing agents, ACE inhibitors, or aliskiren for additive effects. Volume status: be cautious in patients who are dehydrated or on diuretics. Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Karvea can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone): risk of dangerous hyper‑kalemia. - ACE inhibitors or aliskiren: additive renal and potassium effects. - Strong CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan plasma concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal perfusion. - Loop or thiazide diuretics: can enhance hypotensive response. - Lithium: may raise lithium levels, increasing toxicity risk.